Literature DB >> 30121334

Auto-inhibition of adenylyl cyclase 9 (AC9) by an isoform-specific motif in the carboxyl-terminal region.

Adrienn Pálvölgyi1, James Simpson2, Ibolya Bodnár1, Judit Bíró1, Miklós Palkovits3, Tamás Radovits4, Paul Skehel2, Ferenc A Antoni5.   

Abstract

Trans-membrane adenylyl cyclase (tmAC) isoforms show markedly distinct regulatory properties that have not been fully explored. AC9 is highly expressed in vital organs such as the heart and the brain. Here, we report that the isoform-specific carboxyl-terminal domain (C2b) of AC9 inhibits the activation of the enzyme by Gs-coupled receptors (GsCR). In human embryonic kidney cells (HEK293) stably overexpressing AC9, cAMP production by AC9 induced upon the activation of endogenous β-adrenergic and prostanoid GsCRs was barely discernible. Cells expressing AC9 lacking the C2b domain showed a markedly enhanced cAMP response to GsCR. Subsequent studies of the response of AC9 mutants to the activation of GsCR revealed that residues 1268-1276 in the C2b domain were critical for auto-inhibition. Two main species of AC9 of 130 K and ≥ 170 K apparent molecular weight were observed on immunoblots of rodent and human myocardial membranes with NH2-terminally directed anti-AC9 antibodies. The lower molecular weight AC9 band did not react with antibodies directed against the C2b domain. It was the predominant species of AC9 in rodent heart tissue and some of the human samples. There is a single gene for AC9 in vertebrates, moreover, amino acids 957-1353 of the COOH-terminus are encoded by a single exon with no apparent signs of mRNA splicing or editing making it highly unlikely that COOH-terminally truncated AC9 could arise through the processing or editing of mRNA. Thus, deductive reasoning leads to the suggestion that proteolytic cleavage of the C2b auto-inhibitory domain may govern the activation of AC9 by GsCR.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenylyl cyclase, cyclic AMP, myocardium; Auto-inhibition; Heart failure; Limited proteolysis

Mesh:

Substances:

Year:  2018        PMID: 30121334     DOI: 10.1016/j.cellsig.2018.08.010

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  12 in total

Review 1.  Nanometric targeting of type 9 adenylyl cyclase in heart.

Authors:  Autumn N Marsden; Carmen W Dessauer
Journal:  Biochem Soc Trans       Date:  2019-12-20       Impact factor: 5.407

2.  Insights into the Regulatory Properties of Human Adenylyl Cyclase Type 9.

Authors:  Tanya A Baldwin; Yong Li; Cameron S Brand; Val J Watts; Carmen W Dessauer
Journal:  Mol Pharmacol       Date:  2019-01-29       Impact factor: 4.436

3.  Cross-Talk Between the Adenylyl Cyclase/cAMP Pathway and Ca2+ Homeostasis.

Authors:  Jose Sanchez-Collado; Jose J Lopez; Isaac Jardin; Gines M Salido; Juan A Rosado
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

4.  Direct stimulation of adenylyl cyclase 9 by the fungicide imidazole miconazole.

Authors:  James Simpson; Adrienn Pálvölgyi; Ferenc A Antoni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-03       Impact factor: 3.000

Review 5.  Physiological roles of mammalian transmembrane adenylyl cyclase isoforms.

Authors:  Katrina F Ostrom; Justin E LaVigne; Tarsis F Brust; Roland Seifert; Carmen W Dessauer; Val J Watts; Rennolds S Ostrom
Journal:  Physiol Rev       Date:  2021-10-26       Impact factor: 37.312

6.  A Tissue-Engineered Human Psoriatic Skin Model to Investigate the Implication of cAMP in Psoriasis: Differential Impacts of Cholera Toxin and Isoproterenol on cAMP Levels of the Epidermis.

Authors:  Mélissa Simard; Sophie Morin; Geneviève Rioux; Rachelle Séguin; Estelle Loing; Roxane Pouliot
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

7.  Cardiomyocyte Oga haploinsufficiency increases O-GlcNAcylation but hastens ventricular dysfunction following myocardial infarction.

Authors:  Sujith Dassanayaka; Kenneth R Brittian; Bethany W Long; Lauren A Higgins; James A Bradley; Timothy N Audam; Andrea Jurkovic; Anna M Gumpert; Linda T Harrison; István Hartyánszky; Péter Perge; Béla Merkely; Tamás Radovits; John A Hanover; Steven P Jones
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

8.  Structural basis of adenylyl cyclase 9 activation.

Authors:  Chao Qi; Pia Lavriha; Ved Mehta; Basavraj Khanppnavar; Inayathulla Mohammed; Yong Li; Michalis Lazaratos; Jonas V Schaefer; Birgit Dreier; Andreas Plückthun; Ana-Nicoleta Bondar; Carmen W Dessauer; Volodymyr M Korkhov
Journal:  Nat Commun       Date:  2022-02-24       Impact factor: 17.694

9.  Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.

Authors:  David Rhainds; Chris J Packard; Mathieu R Brodeur; Eric J Niesor; Frank M Sacks; J Wouter Jukema; R Scott Wright; David D Waters; Therese Heinonen; Donald M Black; Fouzia Laghrissi-Thode; Marie-Pierre Dubé; Marc A Pfeffer; Jean-Claude Tardif
Journal:  Circ Genom Precis Med       Date:  2021-04-02

10.  Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure.

Authors:  Alex Ali Sayour; Attila Oláh; Mihály Ruppert; Bálint András Barta; Eszter Mária Horváth; Kálmán Benke; Miklós Pólos; István Hartyánszky; Béla Merkely; Tamás Radovits
Journal:  Cardiovasc Diabetol       Date:  2020-09-30       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.